See editorial on page 1718. B iologic therapies, including the anti-tumor necrosis factor (anti-TNF) agents (infliximab, adalimumab, certolizumab pegol, and golimumab), the adhesion molecule inhibitors (vedolizumab and natalizumab), and the p-40 interleukin 12/23 inhibitor ustekinumab, are effective treatments for patients with moderate to severe inflammatory bowel disease (IBD). 1, 2 Nevertheless, up to one-third of patients with Crohn's disease (CD) and ulcerative colitis (UC) show primary non-response (PNR) to biologic therapies, and up to 50% of patients after an initial clinical response stop therapy for either secondary loss of response (SLR) or a serious adverse event. 3, 4 Both PNR and SLR are due to either pharmacokinetic (PK) or pharmacodynamic (PD) problems. PK issues are associated with inadequate drug exposure, often because of the development of antidrug antibodies (ADA), whereas PD issues are typically related to inflammatory process unrelated to the targeted immunoinflammatory pathway. 5, 6 Numerous studies have demonstrated a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes, whereas low or undetectable drug concentrations can lead to immunogenicity and treatment failure (Tables 1-3, Supplementary  Table 1) . Therapeutic drug monitoring (TDM), defined as the assessment of drug concentrations and ADA, is an important tool for optimizing biologic therapy. Reactive TDM has rationalized the management of PNR and SLR and has proven more cost-effective when compared with empiric dose escalation. [96] [97] [98] [99] [100] [101] [102] Preliminary data suggest that proactive TDM, with drug titration to a target trough concentration, performed in patients with clinical response/remission can also improve the efficacy of anti-TNFs. 38, 39, 103, 104 Moreover, proactive TDM may also improve the cost-effectiveness and safety of biologic therapy via the implementation of a de-escalation strategy in patients with supratherapeutic drug concentrations by reducing the dose, increasing the time interval, and/or stopping the immunomodulator in patients on combination therapy (optimized monotherapy). 39, 82, [105] [106] [107] However, there are still some limitations when applying TDM into clinical practice, such as when to use TDM, proper interpretation and application of the results, and the identification of the optimal window/ thresholds to target. These therapeutic windows or thresholds appear to vary on the basis of the outcome of interest and the IBD phenotype (Tables 1 and 2,  Supplementary Table 1) . Moreover, most of the data on implementation of TDM refer to anti-TNF therapies and the maintenance phase of treatment.
We aimed to reach a consensus on when and how to use TDM of biologic therapies during different phases of the treatment (ie, induction, post-induction, and maintenance therapy) and sought to identify clinically relevant drug concentrations and ADA thresholds to help physicians apply TDM in clinical practice.
Methods
We applied a modified Delphi method to establish consensus similar to that described in the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program. 108 A comprehensive literature review was performed regarding the use of TDM of biologic therapies in IBD by using PubMed and Medline databases. We used the following search terms: "inflammatory bowel disease"; "Crohn's disease"; "ulcerative colitis"; "anti-drug antibodies"; "therapeutic drug monitoring" AND "infliximab" OR "adalimumab" OR "certolizumab pegol" OR "golimumab" OR "vedolizumab" OR "ustekinumab". The literature was then presented to a panel of 13 international IBD specialists. Subsequently, on the basis of this review, 28 statements were formulated (K.P., A.S.C, C.A.S.) describing when and how to apply TDM in clinical practice. An Expert Consensus Development Meeting consisting of members of the BRIDGe group (www.BRIDGeIBD.com) and TDM specialists was held in New Orleans on December 9, 2017 to refine and vote anonymously on the statements. Each statement was rated on a scale of 1-10 (1 ¼ strongly disagree, 10 ¼ strongly agree). Statements were accepted if 80% or more of the participants agreed with a score 7. If less than 80% of the panelists agreed with a score 7, statements were discussed and revised on the basis of the available evidence, followed by a second round of voting. The word appropriate was used for each statement to suggest that application of TDM for treatment optimization in a particular clinical scenario is a good option. However, these are not recommendations applicable to every patient.
Results
The panel reached consensus on 24 of 28 statements (86%) ( Tables 4 and 5 ).
Scenarios When Therapeutic Drug Monitoring of Biologic Therapies Should Be Performed
Anti-tumor necrosis factor therapy. On the basis of the literature review, consensus was reached on all 4 statements regarding anti-TNFs (Table 4 ).
1. It is appropriate to order drug/antibody concentration testing in responders at the end of induction for all anti-TNFs.
2. It is appropriate to order drug/antibody concentration testing at least once during maintenance for patients on all anti-TNFs.
3. It is appropriate to order drug/antibody concentration testing of anti-TNFs at the end of induction in primary non-responders.
4. It is appropriate to order drug/antibody concentration testing for all anti-TNFs in patients with confirmed secondary loss of response.
Numerous studies have demonstrated a positive correlation between anti-TNF drug concentrations and favorable therapeutic outcomes (Tables 1 and 2,  Supplementary Table 1) . However, the great majority of TDM studies refer to infliximab. A large retrospective study showed that at least one TDM, either proactive and/or reactive of infliximab compared with lack of any TDM, was associated with less treatment failure. 109 Several studies have shown that reactive TDM can better identify the cause and consequently manage SLR to anti-TNF therapy, although the data for PNR are more scarce. 4, 5, 8, 10, 110 Reactive TDM to guide infliximab dose adjustment compared with clinical decision-making alone is associated with higher post-adjustment clinical response and endoscopic remission and fewer hospitalizations. 37 Moreover, reactive TDM of infliximab was found more cost-effective than using clinical symptoms alone to guide therapeutic decisions. 99, 101, 102, 111 Proactive TDM of infliximab compared with empiric dose escalation and/or reactive TDM was found to be associated with increased drug retention. 39 The landmark randomized controlled trial (RCT), Trough Concentration Adapted Infliximab Treatment (TAXIT), despite failing to meet its primary endpoint, showed that proactive TDM of infliximab compared with clinically based dosing was associated with lower frequency of undetectable drug concentrations and lower risk of relapse. 104 In addition, in patients with CD and subtherapeutic drug concentrations, a one-time dose optimization improved clinical remission rates and C-reactive protein. 104 Furthermore, proactive compared with reactive TDM of infliximab was associated with greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions. 38 Recently, proactive after reactive TDM of infliximab was found to be associated with greater drug persistence and fewer IBDrelated hospitalizations than reactive TDM alone. 103 Proactive TDM can also efficiently guide immunomodulator withdrawal in patients on combination therapy. This concept of optimized monotherapy was introduced in a retrospective study showing that patients with infliximab concentrations 5 mg/mL had similar drug persistence when treated with infliximab monotherapy or combination therapy with an immunomdulator 5 and is further supported by a recent post hoc analysis of the RCT Study of Biologic and Immunomodulator Naïve Patients in Crohn's Disease (SONIC), which demonstrated that patients stratified by infliximab trough quartiles had comparable outcomes regardless of concomitant azathioprine. 112 Vedolizumab. Consensus was reached on only 2 of 4 statements regarding vedolizumab ( vedolizumab concentrations are associated with better therapeutic outcomes ( Table 2) . [90] [91] [92] 113 In particular, a large single-center retrospective cohort study of 179 patients (66 with UC and 113 with CD) showed that higher vedolizumab trough concentrations at weeks 2 and 6 were associated with a higher probability of attaining endoscopic healing, clinical response and biologic response, or remission assessed at week 14 for UC and week 22 for CD. 90 A multicenter prospective observational study identified a vedolizumab trough concentration cutoff of 18 mg/mL at week 6 as the only independent variable associated with mucosal healing within the first year of treatment. 91 Currently, there are no studies comparing either proactive or reactive TDM with symptom-based vedolizumab optimization.
Ustekinumab. Consensus was reached on only 2 of 4 statements regarding ustekinumab (Table 4). 11. It is appropriate to order drug/antibody concentration testing for ustekinumab in nonresponders at the end of induction (at 8 weeks).
12. It is appropriate to order drug/antibody concentration testing for ustekinumab in patients with confirmed secondary loss of response.
The current evidence supporting the role of TDM regarding ustekinumab is based on 2 exposure-response relationship studies showing that higher ustekinumab concentrations correlate to better therapeutic outcomes (Table 2) . 49, 89 At this time, there are still no studies comparing either proactive or reactive TDM with empiric ustekinumab optimization.
Assays, Drug Concentrations, and Anti-Drug Antibodies
General. Consensus was reached on all 4 statements regarding the use of biologic drug concentrations and anti-drug antibodies (Table 5). 13. There is no difference in indication for ordering drug/antibody concentrations or interpretation of results for biosimilars or originator drug.
Current data suggest that infliximab enzyme-linked immunosorbent assays (ELISAs) for evaluating either drug concentrations or antibodies to infliximab (ATI) are suitable for monitoring the infliximab biosimilars SB2 and CT-P13. [114] [115] [116] [117] 14. The threshold drug concentration may vary depending on disease phenotype and desired therapeutic outcome.
Numerous studies have shown an association between higher induction or maintenance biologic drug concentrations and favorable therapeutic outcomes in IBD (Tables 1 and 2, Supplementary Table 1) . Current exposure-response relationship studies suggest that biologic drug concentration thresholds and ranges appear to differ depending on treatment goals and/or disease phenotypes. In general, higher drug concentrations tend to be associated with more stringent outcomes, and higher drug concentrations appear to be needed for phenotypes with a higher inflammatory burden, such as fistulizing CD (Tables 1 and 2 , Supplementary Table 1, Figure 1 ).
15. In the presence of adequate trough drug concentrations, anti-drug antibodies are unlikely to be clinically relevant.
A study from Steenholdt et al 118 showed that most ATI detected via the drug-tolerant homogeneous mobility-shift assay (HMSA) lack neutralizing potential when tested via a functional cell-based reporter-gene assay, suggesting that they may not be clinically significant. A post hoc analysis of the TAXIT study, which investigated the additional benefit of a drug-tolerant assay, concluded that although it allowed closer followup of ATI concentrations and identification of true transient versus persistent antibodies, it offered no clinical benefit over a drug-sensitive assay. 119 Nevertheless, other studies have suggested that "double positive" patients (with positive ATI and drug on board) may be prone to SLR or lack of mucosal healing. 60, 67, 120 16. Other than for ATI, there are not enough data to recommend a threshold for high anti-drug antibody titers for the biologic drugs.
Numerous studies have shown that ADA are associated with subtherapeutic drug trough concentrations, loss of response, and lack of recapture of response after dose escalation (Table 3) . 10 ,12-17,21,23,27-29,31-33, 37,56-58,60,63,67,73,75,80-88 However, the great majority of them and specifically the ones suggesting a threshold of high-titer ADA refer to ATI (Table 3) .
Infliximab. Consensus was reached on all statements regarding infliximab concentrations and ATI (Table 5) . 17 . The current evidence suggests that the variability of infliximab concentrations between the different assays is unlikely to be clinically significant. 19. The minimal trough concentration for infliximab post-induction at week 14 should be greater than 3 mg/mL, and concentrations greater than 7 mg/mL are associated with an increased likelihood of mucosal healing.
(13/13)
20. During maintenance the minimal trough concentration for infliximab for patients in remission should be greater than 3 mg/mL. For patients with active disease, infliximab should generally not be abandoned unless drug concentrations are greater than 10 mg/mL.
(12/13)
21. In the absence of detectable infliximab, high titer anti-infliximab antibodies require a change of therapy. Low level antibodies can sometimes be overcome. For the ANSER assay, a high titer antiinfliximab antibody at trough is defined as 10 U/mL, for RIDAscreen the cutoff is 200 ng/mL, and for InformTx/Lisa Tracker the cutoff is 200 ng/mL. For other assays, there are insufficient data to define an adequate cutoff for a high titer anti-infliximab antibody.
(13/13)
Adalimumab 22. The minimum drug concentration at week 4 for adalimumab should at least be 5 mg/mL. Drug concentrations greater than 7 mg/ml are associated with an increased likelihood of mucosal healing.
(10/12)
a 23. During maintenance the minimum trough concentration for adalimumab for patients in remission should be greater than 5 mg/mL. For patients with active disease, adalimumab should generally not be abandoned unless drug concentrations are greater than 10 mg/mL.
(12/12)
Certolizumab pegol 24. The minimum concentrations for certolizumab pegol at week 6 should be greater than 32 mg/mL. 100 (12/12) 25. During maintenance the minimum trough concentration for certolizumab pegol for patients in remission should be 15 mg/mL.
(11/12)
Golimumab 26. The minimum drug concentration at week 6 for golimumab should at least be 2.5 mg/mL. 92 (11/12) 27. During maintenance the minimum trough concentration for golimumab for patients in remission should be greater than 1 mg/mL.
Vedolizumab/ustekinumab 28. Although there are emerging data that may show an association between drug concentrations and outcomes, they are not sufficient to guide specific induction and maintenance drug concentrations for vedolizumab and ustekinumab other than confirming that there is detectable drug.
(12/12)
a After a second round of voting.
18. There is insufficient evidence that inter-assay drug concentration results are comparable for biologic drugs other than for infliximab.
Current evidence suggests that although absolute drug concentrations can differ between different assays, including the commonly used ELISA, radioimmunoassay, HMSA, and the recently developed electrochemiluminescence immunoassay, they correlate well and generally lead to the same therapeutic decision. 83, 118, [121] [122] [123] However, these data refer mostly to infliximab, whereas there are only scarce data for adalimumab and none for non-anti-TNF agents.
The minimal trough concentration for infliximab
post-induction at week 14 should be greater than 3 mg/mL, and concentrations greater than 7 mg/ mL are associated with an increased likelihood of mucosal healing.
These drug concentration thresholds were mainly based on infliximab exposure-response relationship studies depicted in Supplementary Table 1. 21. In the absence of detectable infliximab, high-titer ATI require a change of therapy. Low-level antibodies can sometimes be overcome. For the ANSER assay, a high-titer ATI at trough is defined as 10 U/ mL, for RIDAscreen the cutoff is 200 ng/mL, and for InformTx/Lisa Tracker the cutoff is 200 ng/mL.
For other assays, there are insufficient data to define an adequate cutoff for a high-titer ATI.
Differences in assay methodology result in varying sensitivity to detect ADA and discrepancies when reporting ADA titers. 122 Therefore, clinically relevant ADA cutoffs are assay specific, referring mostly to ELISAs and the HMSA (Table 3) . Vande Casteele et al 63 showed that ATI >9.1 U/mL (measured with the HMSA) at time of loss of response resulted in a likelihood ratio of 3.6 for an unsuccessful intervention, suggesting these ATI are sustained and probably very hard to overcome. Moreover, Yanai et al 10 showed ATI >9 mg/mL-eq can identify patients who do not respond to an increased drug dosage with 90% specificity. In addition, a small retrospective study of IBD patients in whom infliximab was optimized, either proactively or reactively, to overcome immunogenicity showed that an ATI titer <8.8 U/mL (measured with the HMSA) was associated with drug retention, suggesting that lower-titer ATI can often be overcome with dose intensification. 86 A post hoc analysis of the TAXIT trial showed that ATI >222 ng/mL-eq (measured with an in-house developed drug-tolerant ELISA) was not possible to be overcome after infliximab optimization. 119 Adalimumab. Consensus was reached on all 2 statements regarding adalimumab concentrations and antibodies to adalimumab (Table 5). 22. The minimum drug concentration at week 4 for adalimumab should at least be 5 mg/mL. Drug concentrations greater than 7 mg/mL are associated with an increased likelihood of mucosal healing.
23. During maintenance the minimum trough concentration for adalimumab for patients in remission should be greater than 5 mg/mL. For patients with active disease adalimumab should generally not be abandoned unless drug concentrations are greater than 10 mg/mL.
These drug concentration thresholds were based mainly on adalimumab exposure-response relationship studies depicted in Table 1 .
Certolizumab pegol. Consensus was reached on all 2 statements regarding certolizumab pegol concentrations and antibodies to certolizumab pegol (Table 5 ).
24. The minimum concentrations for certolizumab pegol at week 6 should be greater than 32 mg/mL.
25. During maintenance the minimum trough concentration for certolizumab pegol for patients in remission should be 15 mg/mL.
These drug concentration thresholds were based on certolizumab pegol exposure-response relationship studies depicted in Table 2 .
Golimumab. Consensus was reached on all 2 statements regarding golimumab concentrations and antibodies to golimumab (Table 5 ).
26. The minimum drug concentration at week 6 for golimumab should at least be 2.5 mg/mL.
27. During maintenance the minimum trough concentration for golimumab for patients in remission should be greater than 1 mg/mL.
These drug concentration thresholds were based on exposure-response relationship studies depicted in Table 2 .
Vedolizumab and ustekinumab. Consensus was reached on the statement regarding vedolizumab and ustekinumab concentrations and antibodies to vedolizumab or ustekinumab (Table 5 ).
Although there are emerging data that may show
an association between drug concentrations and outcomes, they are not sufficient to guide specific induction and maintenance drug concentrations for vedolizumab and ustekinumab other than confirming that there is detectable drug.
At the time of the consensus meeting there were only limited data available from exposure-response relationship studies to suggest a clinically relevant vedolizumab or ustekinumab (Table 2 ) threshold or range associated with favorable therapeutic outcomes.
Discussion
Unlike for rheumatoid arthritis and psoriasis, there are only a limited number of biologic agents approved for the treatment of IBD. In addition, current data demonstrate that patients who fail anti-TNF therapies do no respond as well to subsequent agents. 124, 125 Thus, optimizing the use of biologic therapies is of the utmost importance. TDM is one strategy to optimize biologics and maximize their effectiveness. Reactive TDM can better explain and manage SLR, and there is emerging evidence that proactive TDM further improves outcomes and is being used more frequently. 126, 127 In the recent American Gastroenterological Association guidelines, no recommendation was made regarding proactive TDM of anti-TNFs for patients who have quiescent disease because of a "knowledge gap". 96 However, the IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group recommended that in patients in clinical remission after anti-TNF therapy induction, TDM should be considered to guide management, and also TDM should be considered periodically in patients in clinical remission if the results are likely to impact management. 97 Although well-designed large prospective studies are lacking, there are preliminary data mainly from retrospective studies that demonstrate that proactive TDM is associated with better therapeutic outcomes compared with empiric dose optimization and/or reactive TDM. 38, 39, 103, 104, 128 Furthermore, numerous retrospective studies 23, 24, 26, 29, [31] [32] [33] 67, 73, 74, [77] [78] [79] 129, 130 and some post hoc analyses of RCTs [47] [48] [49] 71, 76, 94, 131, 132 have shown that higher biologic drug concentrations are associated with favorable short-term and long-term therapeutic outcomes in IBD (Supplementary Table 1, Tables 1 and  2 ). There do appear to be certain clinical scenarios that proactive TDM of anti-TNF therapy can efficiently guide therapeutic decisions, such as treatment de-escalation, 133 the application of optimized monotherapy instead of combo therapy with immunomodulator, 82 restarting therapy after a long drug holiday, 27 and treatment cessation on deep remission. 50, 51 Nevertheless, before TDM can be widely applied in clinical practice, there are several obstacles to their regular use including when to use TDM, how to accurately interpret and apply the results of such testing, and in defining the optimal drug concentration thresholds and ranges to target. 134 We believe these consensus statements help address these issues and hope they will aid physicians in better understanding and using TDM.
Major limitations of the evidence and consequently these consensus statements relate to the lack of large prospective studies and RCTs on TDM of biologic therapy applied on different IBD phenotypes and sparse data on induction therapy and on biologic agents other than infliximab and adalimumab. Moreover, it is unclear whether trough concentrations are the best predictor of initial response to biologics, compared with peak drug concentrations or total drug exposure. However, in the absence of RCTs, consensus guidelines synthesizing the literature and extrapolating from available data serve to support clinicians in clinical decision-making.
Further RCTs to establish the utility of proactive TDM, particularly during the induction phase, should be performed. Additional future directions should include the development of accurate, easily accessible, and affordable rapid assays and dashboards to allow fast dosing adaptation and incorporation of predictive PK models based on patient and disease characteristics. 66, 135 In conclusion, there is a growing body of evidence that demonstrates the clinical utility of TDM of biologic therapy in IBD. This is a big step toward personalized medicine and optimizing the care of patients with IBD. Although more prospective data are needed especially for proactive TDM, induction therapy, and non-anti-TNF biologics, these consensus statements provide a practical guide to apply TDM for optimizing biologic therapy in patients with IBD. 
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